Atreca (BCEL) Gets a Buy Rating from Stifel Nicolaus

In a report issued on March 4, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Atreca (BCELResearch Report), with a price target of $14.00. The company’s shares closed last Friday at $5.20.

According to TipRanks.com, Willey is a 5-star analyst with an average return of 17.6% and a 46.8% success rate. Willey covers the Healthcare sector, focusing on stocks such as Inovio Pharmaceuticals, AbCellera Biologics, and Nurix Therapeutics.

Currently, the analyst consensus on Atreca is a Strong Buy with an average price target of $23.00, which is a 1269.0% upside from current levels. In a report issued on March 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.

See the top stocks recommended by analysts >>

Atreca’s market cap is currently $193.2M and has a P/E ratio of -1.86.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA.

Read More on BCEL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed